Treatment for cutaneous metastases
The present invention provides methods for treating cutaneous metastases. In one aspect, the method can include identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering an IRM compound to the treatment area in an amount effective for treating the lesion. In another aspect, the method can include identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering a TLR7 agonist to the treatment area in an amount effective for treating the lesion. In another aspect, the method can include identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering a TLR8 agonist to the treatment area in an amount effective for treating the lesion.
1. A method of treating a cutaneous metastasis derived from a breast cancer tumor in a patient in need of such treatment, comprising:
(a) identifying a treatment area that comprises one or more lesions containing metastatic cells; and
(b) administering an immune response modifier (IRM) compound selected from the group consisting of: 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine and 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol to the treatment area in an amount effective for treating the lesion.
2. The method of claim 1 wherein the IRM compound is administered topically.
3. The method of claim 1 wherein the IRM compound is 4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol.
4. The method of claim 1 wherein the IRM compound is administered at least once per week.
5. The method of claim 1 wherein the IRM compound is administered at least five
times per week.
6. The method of claim 1 wherein the IRM compound is administered for at least four weeks.
7. The method of claim 1 wherein the IRM compound is administered for at least six months.
8. The method of claim 1 wherein the breast cancer tumor is Her2/neu-positive.
9. The method of claim 1 wherein the breast cancer tumor is Her2/neu-negative.